Edwards Lifesciences (XSWX:EW) Long-Term Debt: CHF471 Mil (As of Mar. 2026)


XSWX:EW Edwards Lifesciences Corp XSWX:EW
97 GF Score
Price CHF72.91
GF Value CHF75.73
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Long-Term Debt?

Edwards Lifesciences XSWX:EW +0.37% 97 Long-Term Debt is CHF471 Mil as of Mar. 2026. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review.

Edwards Lifesciences's Long-Term Debt for the quarter that ended in Mar. 2026 was CHF471 Mil.

Edwards Lifesciences's quarterly Long-Term Debt increased from Sep. 2025 (CHF476 Mil) to Dec. 2025 (CHF477 Mil) but then declined from Dec. 2025 (CHF477 Mil) to Mar. 2026 (CHF471 Mil).

Edwards Lifesciences's annual Long-Term Debt increased from Dec. 2023 (CHF516 Mil) to Dec. 2024 (CHF533 Mil) but then declined from Dec. 2024 (CHF533 Mil) to Dec. 2025 (CHF477 Mil).

Edwards Lifesciences  (XSWX:EW) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Edwards Lifesciences Long-Term Debt Related Terms

Edwards Lifesciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Long-Term Debt Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 548.64 555.51 516.29 532.91 476.79

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 528.22 486.29 476.23 476.79 471.20
XSWX:EW
97GF Score
Edwards Lifesciences Corp XSWX:EW
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF471 Mil mean?
Edwards Lifesciences (XSWX:EW) has a Long-Term Debt of CHF471 Mil as of Mar. 2026.
Is Edwards Lifesciences' Long-Term Debt too high?
Edwards Lifesciences' current Long-Term Debt is CHF471 Mil. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Long-Term Debt compare to DXCM and GEHC?
Edwards Lifesciences' Long-Term Debt of CHF471 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Edwards Lifesciences's current Long-Term Debt is CHF471 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Long-Term Debt of CHF471 Mil. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current Long-Term Debt is CHF471 Mil. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Long-Term Debt is CHF471 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.

Key valuation signals for XSWX:EW:

  • Long-Term Debt: CHF471 Mil
  • GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for XSWX:EW

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.91
Price
CHF75.73
GF Value